Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Agustin Oterino"'
Autor:
Francisco Gascón-Giménez, Carmen Alcalá, Lluís Ramió-Torrentà, Paloma Montero, Jorge Matías-Guiu, Irene Gómez-Estevez, Celia Oreja-Guevara, Sara Gil-Perotín, Yolanda Blanco, María Carcelén, Carlos Quintanilla-Bordás, Lucienne Costa, Luisa Maria Villar, Jose Enrique Martínez-Rodriguez, José Andrés Domínguez, Carmen Calles, Inés González, Javier Sotoca, Agustin Oterino, Celia Lucas-Jimenez, Francisco Pérez-Miralles, Bonaventura Casanova
Publikováno v:
Frontiers in Neurology, Vol 14 (2023)
IntroductionRituximab (RTX) is considered a potential therapeutic option for relapsing-remitting (RRMS) and progressive forms (PMS) of multiple sclerosis (MS). The main objective of this work was to investigate the effectiveness and safety of rituxim
Externí odkaz:
https://doaj.org/article/a88c93d629e84c54ae63a9bf5ae7db28
Autor:
Victor Obach, Fernando Velasco, Rocio Alvarez Escudero, María Martín Bujanda, Sonsoles Aranceta, Neus Fabregat, Teresa Marco, Aintzine Ruisanchez, Natalia Roncero, Ane Mínguez-Olaondo, Marta Ruibal, Daniel Guisado-Alonso, Antia Moreira, Elisa Cuadrado-Godia, Amaya Echeverria, Izaro Kortazar Zubizarreta, Alba López-Bravo, Nuria Riesco, Lucia González-Fernández, Nuria Pola, Paula Manera, Ángel Luis Guerrero-Peral, Agustín Oterino Duran, Yésica González-Osorio, Rosario Armand, Santiago Fernández-Fernández, David García-Azorín, Juan Carlos García-Moncó
Publikováno v:
The Journal of Headache and Pain, Vol 24, Iss 1, Pp 1-11 (2023)
Abstract Background Galcanezumab has shown efficacy and effectiveness in the treatment of episodic and chronic migraine (CM), however, the population represented in randomized clinical trials (RCTs) differs from the population observed in real-world
Externí odkaz:
https://doaj.org/article/b004166f59b241048d489a487c035582
Autor:
José E. Meca-Lallana, José M. Prieto González, Ana B. Caminero Rodríguez, Javier Olascoaga Urtaza, Ana M. Alonso, Eduardo Durán Ferreras, Raúl Espinosa, Julio Dotor, Mercedes Romera, Adrián Ares Luque, Domingo Pérez Ruiz, Carmen Calles, Miguel A. Hernández, Miguel Hervás García, Amelia Mendoza Rodríguez, Yasmina Berdei Montero, Nieves Téllez, Nicolás Herrera Varó, Javier Sotoca, Silvia Presas-Rodríguez, Luis A. Querol Gutierrez, Mariona Hervás Pujol, Jordi Batlle Nadal, Gisela Martín Ozaeta, Laura Gubieras Lillo, Sergio Martínez Yélamos, Lluís Ramió-Torrentà, Javier Mallada Frechin, Antonio Belenguer Benavides, Francisco Gascón-Giménez, Bonaventura Casanova, Lamberto Landete Pascual, Leticia Berenguer, Laura Navarro, Montserrat Gómez Gutierrez, Carmen Durán, Ana Rodríguez Regal, Elena Álvarez, Daniel A. García-Estévez, Ana M. López Real, Miguel A. Llaneza González, María E. Marzo Sola, José L. Sánchez-Menoyo, Agustín Oterino, Ramón Villaverde González, Tamara Castillo-Triviño, Amaya Álvarez de Arcaya, Cristina Llarena
Publikováno v:
Neurology and Therapy, Vol 12, Iss 6, Pp 2177-2193 (2023)
Abstract Introduction Teriflunomide is a once-daily oral immunomodulator approved for relapsing forms of multiple sclerosis (MS) or relapsing–remitting multiple sclerosis (RRMS; depending on the local label), based on extensive evidence from clinic
Externí odkaz:
https://doaj.org/article/0d5e12714aa14ddbb6e6eadf49cbbed1
Autor:
Agustin Oterino Duran, Joaquin Peña Martinez, Dionisio Fernández Uría, Walter Javier Villafani Echazú, Dulce Maria Solar Sanchez, Pedro Oliva Nacarino, Vicente González Quintanilla, Roberto Suárez Moro
Publikováno v:
Revista de Neurología. 63:19
Objetivo. Evaluar la efectividad y seguridad del fingolimod en la practica clinica habitual en la region de Asturias y Cantabria (Espana). Pacientes y metodos. Estudio retrospectivo y multicentrico de pacientes con esclerosis multiple recurrente remi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::25e15fd57d6d2faad5565b7c7a536861
https://doi.org/10.33588/rn.63s01.2016256
https://doi.org/10.33588/rn.63s01.2016256
Autor:
Robert Belvís, Pablo Irimia, Patricia Pozo-Rosich, Carmen González-Oria, Antonio Cano, Javier Viguera, Belén Sánchez, Francisco Molina, Isabel Beltrán, Agustín Oterino, Elisa Cuadrado, Angel Gómez-Camello, Miguel Alberte-Woodward, Carmen Jurado, Teresa Oms, David Ezpeleta, Javier Díaz de Terán, Noemí Morollón, Germán Latorre, Marta Torres-Ferrús, Alicia Alpuente, Raquel Lamas, Carlos Toledano, Rogelio Leira, Sonia Santos, Margarita Sánchez del Río
Publikováno v:
The Journal of Headache and Pain, Vol 22, Iss 1, Pp 1-8 (2021)
Abstract Background Erenumab was approved in Europe for migraine prevention in patients with ≥ 4 monthly migraine days (MMDs). In Spain, Novartis started a personalized managed access program, which allowed free access to erenumab before official r
Externí odkaz:
https://doaj.org/article/fcecd02650084384bd50ba7605c09f88
Autor:
Inmaculada Toboso, Amalia Tejeda-Velarde, Roberto Alvarez-Lafuente, Rafael Arroyo, Harald Hegen, Florian Deisenhammer, Susana Sainz de la Maza, José C. Alvarez-Cermeño, Guillermo Izquierdo, Dolores Paramo, Pedro Oliva, Bonaventura Casanova, Eduardo Agüera-Morales, Diego Franciotta, Matteo Gastaldi, Oscar Fernández, Patricia Urbaneja, José M. Garcia-Dominguez, Fernando Romero, Alicia Laroni, Antonio Uccelli, Angel Perez-Sempere, Albert Saiz, Yolanda Blanco, Daniela Galimberti, Elio Scarpini, Carmen Espejo, Xavier Montalban, Ludwig Rasche, Friedemann Paul, Inés González, Elena Álvarez, Cristina Ramo, Ana B. Caminero, Yolanda Aladro, Carmen Calles, Pablo Eguía, Antonio Belenguer-Benavides, Lluis Ramió-Torrentà, Ester Quintana, José E. Martínez-Rodríguez, Agustín Oterino, Carlos López de Silanes, Luis I. Casanova, Lamberto Landete, Jette Frederiksen, Gabriel Bsteh, Patricia Mulero, Manuel Comabella, Miguel A. Hernández, Mercedes Espiño, José M. Prieto, Domingo Pérez, María Otano, Francisco Padilla, Juan A. García-Merino, Laura Navarro, Alfonso Muriel, Lucienne Costa Frossard, Luisa M. Villar
Publikováno v:
Frontiers in Neurology, Vol 11 (2020)
Overview: We assessed the role of age and disease activity as new factors contributing to establish the risk of progressive multifocal leucoencephalopathy in multiple sclerosis patients treated with natalizumab in 36 University Hospitals in Europe. W
Externí odkaz:
https://doaj.org/article/c82f6fa684d240fe86a6b469a1788aa1
Publikováno v:
Cephalalgia Reports, Vol 3 (2020)
Background: Methylation of two CpG sites related to neuronal pentraxin II protein (NPTX2) and SH2 domain containing 5 protein (SH2D5), corresponding to two neuroplasticity genes, has been associated to headache chronification. We aimed to investigate
Externí odkaz:
https://doaj.org/article/e13ba7ab3f0047a5b31c94b3dc4b6256
Autor:
Agustín Oterino Durán, Julio Pascual
Publikováno v:
Acta Neurológica Colombiana, Vol 24, Iss 3 supl 1 (2008)
Es evidente que la migraña se presenta con mayor frecuencia en algunos grupos familiares. Su transmisión genética no sigue un comportamiento acorde con las leyes de la herencia mendeliana; en ella intervienen múltiples factores, que son modulados
Externí odkaz:
https://doaj.org/article/c0ec5a44fe134b10937ae97a93380c90